Advancements in mTOR Inhibitors for Non-Small-Cell Lung Cancer: Mechanisms, Efficacy, and Future Perspectives

Abstract

This account comprehensively reviews the recent advancements in the development of mechanistic target of rapamycin (mTOR) inhibitors targeting non-small-cell lung cancer (NSCLC), focusing on their mechanisms, efficacy, and clinical trial statuses. Key small molecules such as RM-018 and RMC-4998 highlight novel approaches in targeting the KRASG12C mutation, offering enhanced potency compared to earlier inhibitors. Traditional and plant-derived compounds, including Fuzi alkaloids, salvianolic acid, and ononin, demonstrate promising antitumor activities through diverse pathways, such as the PI3K/AKT/mTOR signaling axis. Combination therapies targeting dual pathways show synergistic effects, improving treatment efficacy. The role of personalized medicine, driven by genetic profiling and pathway-specific inhibitors, is emphasized as a transformative approach in NSCLC management. These findings highlight the potential of mTOR-targeting agents as a cornerstone in advancing NSCLC therapies.

1 Introduction

2 Small-Molecule mTOR Inhibitors

3 mTOR Inhibitors in Clinical Trials

4 Conclusion and Future Directions

Key words

mTOR - small molecules - rapalogs - clinical trials - cancer

Publikationsverlauf

Eingereicht: 30. November 2024

Angenommen nach Revision: 20. Dezember 2024

Accepted Manuscript online:
20. Dezember 2024

Artikel online veröffentlicht:
12. Februar 2025

• References

• 1 Schulze CJ, Seamon KJ, Zhao Y, Yang YC, Cregg J, Kim D, Tomlinson A, Choy TJ, Wang Z, Sang B, Pourfarjam Y, Lucas J, Cuevas-Navarro A, Ayala-Santos C, Vides A, Li C, Marquez A, Zhong M, Vemulapalli V, Weller C, Gould A, Whalen DM, Salvador A, Milin A, Saldajeno-Concar M, Dinglasan N, Chen A, Evans J, Knox JE, Koltun ES, Singh M, Nichols R, Wildes D, Gill AL, Smith JA. M, Lito P. Science 2023; 381: 794
• 2 Liu B, Zhou H, Tan L, Siu KT. H, Guan X.-Y. Signal Transduction Targeted Ther. 2024; 9: 175
• 3 Ali ES, Mitra K, Akter S, Ramproshad S, Mondal B, Khan IN, Islam MT, Sharifi-Rad J, Calina D, Cho WC. Cancer Cell Int. 2022; 22: 284
• 4 Singh S, Barik D, Lawrie K, Mohapatra I, Prasad S, Naqvi AR, Singh A, Singh G. Int. J. Mol. Sci. 2023; 24: 14960
• 5 Wahbah M, Boroumand N, Castro C, El-Zeky F, Eltorky M. Ann. Diagn. Pathol. 2007; 11: 89
• 6 Gargalionis AN, Papavassiliou KA, Papavassiliou AG. Cells 2023; 12: 2014
• 7 Glaviano A, Foo AS. C, Lam HY, Yap KC. H, Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B, Kulke MH, Baird RD, Prabhu JS, Carbone D, Pecoraro C, Teh DB. L, Sethi G, Cavalieri V, Lin KH, Javidi-Sharifi NR, Toska E, Davids MS, Brown JR, Diana P, Stebbing J, Fruman DA, Kumar AP. Mol. Cancer 2023; 22: 138
• 8 Sanaei M.-J, Razi S, Pourbagheri-Sigaroodi A, Bashash D. Transl. Oncol. 2022; 18: 101364
• 9 Meric-Bernstam F, Gonzalez-Angulo AM. J. Clin. Oncol. 2009; 27: 2278
• 10 Dey R, Chaube U, Bhatt H, Patel B. Small Molecule Drug Design . In Reference Module in Life Sciences . Elsevier; Amsterdam: 2024
• 11 Son B, Lee W, Kim H, Shin H, Park HH. Cell Death Dis. 2024; 15: 696
• 12 Kenfield SA, Wei EK, Stampfer MJ, Rosner BA, Colditz GA. Tob. Control 2008; 17: 198
• 13 Tan AC. Thorac. Cancer 2020; 11: 511
• 14 Zarogoulidis P, Lampaki S, Turner JF, Huang H, Kakolyris S, Syrigos K, Zarogoulidis K. Oncol. Lett. 2014; 8: 2367
• 15 Yu T, Zhao Y, Hu Z, Li J, Chu D, Zhang J, Li Z, Chen B, Zhang X, Pan H, Li S, Lin H, Liu L, Yan M, He X, Yao M. Cancer Res. 2017; 77: 5782
• 16 ClinicalTrials.gov, https://clinicaltrials.gov/search?cond=lung%20cancer&term=mTOR (accessed Jan. 31, 2025)
• 17 Sathe A, Nawroth R. Methods in Molecular Biology 1655. Urothelial Carcinoma: Methods and Protocols . Schulz WA, Hoffmann MJ, Niegisch G. Springer Nature; New York: 2018: 335
• 18 Sakre N, Wildey G, Behtaj M, Kresak A, Yang M, Fu P, Dowlati A. Oncotarget 2017; 8: 5992
• 19 Nokin M.-J, Mira A, Patrucco E, Ricciuti B, Cousin S, Soubeyran I, San José S, Peirone S, Caizzi L, Vietti Michelina S, Bourdon A, Wang X, Alvarez-Villanueva D, Martínez-Iniesta M, Vidal A, Rodrigues T, García-Macías C, Awad MM, Nadal E, Villanueva A, Italiano A, Cereda M, Santamaría D, Ambrogio C. Nat. Commun. 2024; 30: 7554
• 20 Chiarini F, Evangelisti C, McCubrey JA, Martelli AM. Trends Pharmacol. Sci. 2015; 36: 124
• 21 Krencz I, Sebestyen A, Khoor A. Pathol. Oncol. Res. 2020; 26: 35
• 22 von Richter O, Massimini G, Scheible H, Udvaros I, Johne A. Br. J. Clin. Pharmacol. 2016; 82: 1498
• 23 Batrash F, Kutmah M, Zhang J. Exp. Hematol. Oncol. 2023; 12: 93
• 24 Jeong E.-J, Choi JJ, Lee SY, Kim YS. Int. J. Mol. Sci. 2024; 25: 7011
• 25 Kitai H, Choi PH, Yang YC, Boyer JA, Whaley A, Pancholi P, Thant C, Reiter J, Chen K, Markov V, Taniguchi H, Yamaguchi R, Ebi H, Evans J, Jiang J, Lee B, Wildes D, De Stanchina E, Smith JA. M, Singh M, Rosen N. Nat. Commun. 2024; 15: 6076
• 26 Hsu J.-L, Leu W.-J, Hsu L.-C, Hsieh C.-H, Guh J.-H. Oncol. Lett. 2024; 27: 170
• 27 Wagner AJ, Ravi V, Ganjoo KN, Van Tine BA, Riedel RF, Chugh R, Cranmer LD, Gordon EM, Hornick JL, Kwiatkowski DJ, Du H, Grigorian B, Schmid AN, Hou S, Harris K, Desai N, Dickson MA. J. Clin. Oncol. 2019; 37: 11005
• 28 Shaw S, Dey R, Bhatt H, Patel B, Patel S, Dixit N, Chaube U. ChemistrySelect 2024; 9: e202303291
• 29 Zhao L, Wang Y, Sun X, Zhang X, Simone N, He J. Int. J. Mol. Sci. 2024; 25: 2382
• 30 Zhang W, Cai S, Qin L, Feng Y, Ding M, Luo Z, Shan J, Di L. Commun. Biol. 2024; 7: 1118
• 31 Zhou X, Zhou R, Li Q, Jie X, Hong J, Zong Y, Dong X, Zhang S, Li Z, Wu G. Anticancer Drugs 2019; 30: 241
• 32 Wang S, Xu X, Hu Y, Lei T, Liu T. Front. Pharmacol. 2019; 10: 1460
• 33 Ji L, Moghal N, Zou X, Fang Y, Hu S, Wang Y, Tsao MS. Cancer Med. 2023; 12: 5688
• 34 Chen G.-Q, Guo H.-Y, Quan Z.-S, Shen Q.-K, Li X, Luan T. Molecules 2023; 28: 7440
• 35 Gong G, Ganesan K, Xiong Q, Zheng Y. Oxid. Med. Cell. Longevity 2022; 5122448
• 36 Chaube U, Dey R, Shaw S, Patel BD, Bhatt HG. Future Med. Chem. 2022; 23: 1789
• 37 Yu L, Wei J, Liu P. Semin. Cancer Biol. 2022; 85: 69
• 38 Chaube UJ, Rawal R, Jha AB, Variya B, Bhatt HG. Bioorg. Chem. 2021; 106: 104501
• 39 Mohite R, Doshi G. Curr. Cancer Drug Targets 2024; 24: 231
• 40 Cheng H, Zou Y, Ross JS, Wang K, Liu X, Halmos B, Ali SM, Liu H, Verma A, Montagna C, Chachoua A, Goel S, Schwartz EL, Zhu C, Shan J, Yu Y, Gritsman K, Yelensky R, Lipson D, Otto G, Hawryluk M, Stephens PJ, Miller VA, Piperdi B, Perez-Soler R. Cancer Discovery 2015; 5: 1262
• 41 Natarajan SR, Ponnusamy L, Manoharan R. Biochim. Biophys. Acta, Mol. Cell Res. 2022; 1869: 119242
• 42 Hung M.-C, Wang W.-P, Chi Y.-H. Cell Biosci. 2022; 12: 122
• 43 Lastwika KJ, Wilson W, Li QK, Norris J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S, Liu LN, Gills JJ, Dennis PA. Cancer Res. 2016; 76: 227
• 44 Jin L, Chen C, Huang L, Bu L, Zhang L, Yang Q. Clin. Exp. Pharmacol. Physiol. 2021; 48: 508
• 45 Lin Z, Wang Z, Zhou X, Zhang M, Gao D, Zhang L, Wang P, Chen Y, Lin Y, Zhao B, Miao J, Kong F. Cell Death Dis. 2020; 11: 551
• 46 Lee K, Shueng P, Chou C, Lin B, Lin M, Kuo D, Tsai I, Wu S, Lin C. Cancer Sci. 2020; 111: 1652
• 47 Beck JT, Ismail A, Tolomeo C. Cancer Treat. Rev. 2014; 40: 980
• 48 Lückstädt W, Rathod M, Möbus L, Bub S, Lucius R, Elsner F, Spindler V, Arnold P. Res. Sq. 2024; preprint
• 49 Lückstädt W, Bub S, Koudelka T, Pavlenko E, Peters F, Prasath S, Becker-Pauly C, Lucius R, Zunke F, Arnold P. Front. Cell Dev. Biol. 2021; 9: 622390
• 50 Frontiers | Cell Surface Processing of CD109 by Meprin β Leads to the Release of Soluble Fragments and Reduced Expression on Extracellular Vesicles https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2021.622390/full (accessed Nov 26, 2024)
• 51 Lee K.-Y, Kuo T.-C, Chou C.-M, Hsu W.-J, Lee W.-C, Dai J.-Z, Wu S.-M, Lin C.-W. Cells 2021; 10: 28
• 52 Teng Q.-X, Ashar YV, Gupta P, Gadee E, Fan Y.-F, Reznik SE, Wurpel JN. D, Chen Z.-S. Drug Discovery Today 2019; 24: 2086
• 53 Cutsem EV, Eng C, Nowara E, Świeboda-Sadlej A, Tebbutt NC, Mitchell E, Davidenko I, Stephenson J, Elez E, Prenen H, Deng H, Tang R, McCaffery I, Oliner KS, Chen L, Gansert J, Loh E, Smethurst D, Tabernero J. Clin. Cancer Res. 2014; 20: 4240
• 54 Zhao R, Chen M, Jiang Z, Zhao F, Xi B, Zhang X, Fu H, Zhou KJ. Cancer 2015; 6: 623
• 55 Crees ZD, Shearrow C, Lin L, Girard J, Arasi K, Bhoraskar A, Berei J, Eckburg A, Anderson AD, Garcia C, Munger A, Palani S, Smith TJ, Sreenivassappa SB, Vitali C, David O, Puri N. Ther. Adv. Med. Oncol. 2020; 12: 1758835920953731
• 56 Magaway C, Kim E, Jacinto E. Cells 2019; 8: 1584
• 57 Liu F, Gao S, Yang Y, Zhao X, Fan Y, Ma W, Yang D, Yang A, Yu Y. Oncol. Rep. 2018; 39: 1523
• 58 Zhu J, Yao J, Huang R, Wang Y, Jia M, Huang Y. Biochem. Biophys. Res. Commun. 2018; 498: 616
• 59 Liu X, Jiang Q, Liu H, Luo S. Biol. Res. 2019; 52: 7
• 60 Zhao H, Chen G, Ye L, Yu H, Li S, Jiang WG. Int. J. Oncol. 2019; 54: 381
• 61 Bhardwaj M, Cho HJ, Paul S, Jakhar R, Khan I, Lee S.-J, Kim B.-Y, Krishnan M, Khaket TP, Lee HG, Kang SC. Oncotarget 2018; 9: 3278
• 62 Das B, Sarkar N, Bishayee A, Sinha D. Semin. Cancer Biol. 2019; 56: 196
• 63 Wang J, Li J, Cao N, Li Z, Han J, Li L. OncoTargets Ther. 2018; 11: 7777
• 64 Dey R, Shaw S, Bhatt H, Patel B, Yadav R, Chaube U. J. Mol. Struct. 2024; 1318: 139330
• 65 Wu P, Hu Y.-Z. Curr. Med. Chem. 2010; 17: 4326
• 66 Soria J.-C, Shepherd FA, Douillard J.-Y, Wolf J, Giaccone G, Crino L, Cappuzzo F, Sharma S, Gross SH, Dimitrijevic S, Scala LD, Gardner H, Nogova L, Papadimitrakopoulou V. Ann. Oncol. 2009; 20: 1674
• 67 Barbieri F, Albertelli M, Grillo F, Mohamed A, Saveanu A, Barlier A, Ferone D, Florio T. Drug Discovery Today 2014; 19: 458
• 68 Arshad MF, Alam A, Alshammari AA, Alhazza MB, Alzimam IM, Alam MA, Mustafa G, Ansari MS, Alotaibi AM, Alotaibi AA, Kumar S, Asdaq SM. B, Imran M, Deb PK, Venugopala KN, Jomah S. Molecules 2022; 27: 3994
• 69 Dhiman A, Sharma R, Singh RK. Acta Pharm. Sin. B 2022; 12: 3006
• 70 Bluthgen M.-V, Besse B. Eur. Respir. Rev. 2015; 24: 582
• 71 Hoeffer CA, Tang W, Wong H, Santillan A, Patterson RJ, Martinez LA, Tejada-Simon MV, Paylor R, Hamilton SL, Klann E. Neuron 2008; 60: 832
• 72 Wu Q, Lv Q, Liu X, Ye X, Cao L, Wang M, Li J, Yang Y, Li L, Wang S. Front. Pharmacol. 2023; 14: 1083875
• 73 Hausch F, Kozany C, Theodoropoulou M, Fabian A.-K. Cell Cycle 2013; 12: 2366
• 74 Devarakonda S, Pellini B, Verghese L, Park H, Morgensztern D, Govindan R, Suresh R, Oppelt P, Baggstrom MQ, Wu N, Waqar SN. J. Thorac. Dis. 2021; 13: 4054
• 75 Liu X, Mei W, Zhang P, Zeng C. Pharmacol. Res. 2024; 202: 107123
• 76 Lv X, Ma X, Hu Y. Expert Opin. Drug Discovery 2013; 8: 991
• 77 Yang JC.-H, Mok TS. K, Lu S, Nakagawa K, Yamamoto N, Shi Y.-K, Zhang L, Soo RA, Morita S, Tamura T. JTO Clin. Res. Rep. 2021; 2: 100142
• 78 Don AS. A, Zheng XF. S. Rev. Recent Clin. Trials 2011; 6: 24
• 79 Tello TL, Coggshall K, Yom SS, Yu SS. J. Am. Acad. Dermatol. 2018; 78: 445
• 80 Price KA, Azzoli CG, Krug LM, Pietanza MC, Rizvi NA, Pao W, Kris MG, Riely GJ, Heelan RT, Arcila ME, Miller VA. J. Thorac. Oncol. 2010; 5: 1623
• 81 Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer. Emory University; USA: 2012. https://ctv.veeva.com/study/phase-i-ii-trial-of-rad001-plus-docetaxel-in-patients-with-metastatic-or-recurrent-non-small-cell-lu (accessed Jan. 31, 2025)
• 82 Matsuzawa R, Morise M, Ito K, Hataji O, Takahashi K, Koyama J, Kuwatsuka Y, Goto Y, Imaizumi K, Itani H, Yamaguchi T, Zenke Y, Oki M, Ishii M. eClinicalMedicine 2023; 66: 102303
• 83 Temsirolimus: An Overview (accessed Jan. 31, 2025): https://www.sciencedirect.com/topics/medicine-and-dentistry/temsirolimus
• 84 Hotte SJ, Hirte HW. Curr. Pharm. Des. 2002; 8: 2249
• 85 National Lung Matrix Trial: Multi-Drug Phase II Trial in Non-Small Cell (NSC) Lung Cancer (accessed Jan. 31, 2025) https://www.isrctn.com/ISRCTN38344105
• 86 Zhao Z.-Q, Yu Z.-Y, Li J, Ouyang X.-N. Oncol. Lett. 2016; 12: 63
• 87 Gadgeel SM, Wozniak A. Clin. Lung Cancer 2013; 14: 322
• 88 Marshall EA, Ng KW, Anderson C, Hubaux R, Thu KL, Lam WL, Martinez VD. Genomics Data 2015; 6: 145
• 89 Inci TG, Acar S, Turgut-Balik D. Turk. J. Biol. 2024; 48: 112
• 90 Comis RL. The Oncologist 2005; 10: 467
• 91 Dimou A, Bamias A, Gogas H, Syrigos K. Lung Cancer 2019; 133: 56
• 92 Fumarola C, Bonelli MA, Petronini PG, Alfieri RR. Biochem. Pharmacol. 2014; 90: 197
• 93 Cuyler J, Murthy P, Spada NG, McGuire TF, Lotze MT, Xie X.-Q. Drug Discovery Today 2022; 27: 362
• 94 Wei X, Chen Y, Jiang X, Peng M, Liu Y, Mo Y, Ren D, Hua Y, Yu B, Zhou Y, Liao Q, Wang H, Xiang B, Zhou M, Li X, Li G, Li Y, Xiong W, Zeng Z. Mol. Cancer 2021; 20: 7
• 95 Ramalingam SS, Harvey RD, Saba N, Owonikoko TK, Kauh J, Shin DM, Sun S.-Y, Strychor S, Tighiouart M, Egorin MJ, Fu H, Khuri FR. Cancer 2010; 116: 3903
• 96 Xu J.-Q, Fu Y.-L, Zhang J, Zhang K.-Y, Ma J, Tang J.-Y, Zhang Z.-W, Zhou Z.-Y. Front. Pharmacol. 2022; 13: 1037341
• 97 Kirkpatrick DL, Powis G. Antioxid. Redox Signaling 2017; 26: 262
• 98 Luo Q, Wang J, Zhao W, Peng Z, Liu X, Li B, Zhang H, Shan B, Zhang C, Duan C. J. Hematol. Oncol. 2020; 13: 19
• 99 Andonegui-Elguera MA, Alfaro-Mora Y, Cáceres-Gutiérrez R, Caro-Sánchez CH. S, Herrera LA, Díaz-Chávez J. Front. Oncol. 2020; 10: 220
• 100 Kang JI, Hong J.-Y, Lee H.-J, Bae SY, Jung C, Park HJ, Lee SK. PLoS One 2015; 10: e0144368
• 101 El Hage A, Dormond O. Cancers 2021; 13: 1359
• 102 Gatzka MV. Cancers 2018; 10: 155
• 103 Vishwakarma K, Dey R, Bhatt H. Eur. J. Med. Chem. 2023; 249: 115121